First Time Loading...

Cidara Therapeutics Inc
NASDAQ:CDTX

Watchlist Manager
Cidara Therapeutics Inc Logo
Cidara Therapeutics Inc
NASDAQ:CDTX
Watchlist
Price: 13 USD 5.78% Market Closed
Updated: Apr 26, 2024

Intrinsic Value

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. [ Read More ]

The intrinsic value of one CDTX stock under the Base Case scenario is 0.75 USD. Compared to the current market price of 13 USD, Cidara Therapeutics Inc is Overvalued by 94%.

Key Points:
CDTX Intrinsic Value
Base Case
0.75 USD
Overvaluation 94%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Cidara Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CDTX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Cidara Therapeutics Inc

Provide an overview of the primary business activities
of Cidara Therapeutics Inc.

What unique competitive advantages
does Cidara Therapeutics Inc hold over its rivals?

What risks and challenges
does Cidara Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Cidara Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Cidara Therapeutics Inc.

Provide P/S
for Cidara Therapeutics Inc.

Provide P/E
for Cidara Therapeutics Inc.

Provide P/OCF
for Cidara Therapeutics Inc.

Provide P/FCFE
for Cidara Therapeutics Inc.

Provide P/B
for Cidara Therapeutics Inc.

Provide EV/S
for Cidara Therapeutics Inc.

Provide EV/GP
for Cidara Therapeutics Inc.

Provide EV/EBITDA
for Cidara Therapeutics Inc.

Provide EV/EBIT
for Cidara Therapeutics Inc.

Provide EV/OCF
for Cidara Therapeutics Inc.

Provide EV/FCFF
for Cidara Therapeutics Inc.

Provide EV/IC
for Cidara Therapeutics Inc.

Show me price targets
for Cidara Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Cidara Therapeutics Inc?

How accurate were the past Revenue estimates
for Cidara Therapeutics Inc?

What are the Net Income projections
for Cidara Therapeutics Inc?

How accurate were the past Net Income estimates
for Cidara Therapeutics Inc?

What are the EPS projections
for Cidara Therapeutics Inc?

How accurate were the past EPS estimates
for Cidara Therapeutics Inc?

What are the EBIT projections
for Cidara Therapeutics Inc?

How accurate were the past EBIT estimates
for Cidara Therapeutics Inc?

Compare the revenue forecasts
for Cidara Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Cidara Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Cidara Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Cidara Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Cidara Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Cidara Therapeutics Inc with its peers.

Analyze the financial leverage
of Cidara Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Cidara Therapeutics Inc.

Provide ROE
for Cidara Therapeutics Inc.

Provide ROA
for Cidara Therapeutics Inc.

Provide ROIC
for Cidara Therapeutics Inc.

Provide ROCE
for Cidara Therapeutics Inc.

Provide Gross Margin
for Cidara Therapeutics Inc.

Provide Operating Margin
for Cidara Therapeutics Inc.

Provide Net Margin
for Cidara Therapeutics Inc.

Provide FCF Margin
for Cidara Therapeutics Inc.

Show all solvency ratios
for Cidara Therapeutics Inc.

Provide D/E Ratio
for Cidara Therapeutics Inc.

Provide D/A Ratio
for Cidara Therapeutics Inc.

Provide Interest Coverage Ratio
for Cidara Therapeutics Inc.

Provide Altman Z-Score Ratio
for Cidara Therapeutics Inc.

Provide Quick Ratio
for Cidara Therapeutics Inc.

Provide Current Ratio
for Cidara Therapeutics Inc.

Provide Cash Ratio
for Cidara Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Cidara Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Cidara Therapeutics Inc?

What is the current Free Cash Flow
of Cidara Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Cidara Therapeutics Inc.

Financials

Balance Sheet Decomposition
Cidara Therapeutics Inc

Current Assets 57.7m
Cash & Short-Term Investments 48.7m
Receivables 2.9m
Other Current Assets 6.1m
Non-Current Assets 5.8m
PP&E 4.7m
Other Non-Current Assets 1.1m
Current Liabilities 35.6m
Accounts Payable 3.7m
Accrued Liabilities 17.3m
Other Current Liabilities 14.6m
Non-Current Liabilities 19.8m
Other Non-Current Liabilities 19.8m
Efficiency

Earnings Waterfall
Cidara Therapeutics Inc

Revenue
56.5m USD
Cost of Revenue
-44.2m USD
Gross Profit
12.3m USD
Operating Expenses
-44m USD
Operating Income
-31.7m USD
Other Expenses
300k USD
Net Income
-31.4m USD

Free Cash Flow Analysis
Cidara Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

CDTX Profitability Score
Profitability Due Diligence

Cidara Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
ROIC is Increasing
Negative 1-Year Revenue Growth
Negative Revenue Growth Forecast
21/100
Profitability
Score

Cidara Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

CDTX Solvency Score
Solvency Due Diligence

Cidara Therapeutics Inc's solvency score is 68/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Short-Term Solvency
Long-Term Solvency
68/100
Solvency
Score

Cidara Therapeutics Inc's solvency score is 68/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CDTX Price Targets Summary
Cidara Therapeutics Inc

Wall Street analysts forecast CDTX stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CDTX is 5.36 USD with a low forecast of 3.03 USD and a high forecast of 7.35 USD.

Lowest
Price Target
3.03 USD
77% Downside
Average
Price Target
5.36 USD
59% Downside
Highest
Price Target
7.35 USD
43% Downside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CDTX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CDTX Price
Cidara Therapeutics Inc

1M 1M
-12%
6M 6M
-20%
1Y 1Y
-37%
3Y 3Y
-71%
5Y 5Y
-72%
10Y 10Y
-96%
Annual Price Range
13
52w Low
10.25
52w High
28.4
Price Metrics
Average Annual Return -17.47%
Standard Deviation of Annual Returns 44.17%
Max Drawdown -90%
Shares Statistics
Market Capitalization 1.2B USD
Shares Outstanding 90 287 400
Percentage of Shares Shorted 0.22%

CDTX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Cidara Therapeutics Inc Logo
Cidara Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.2B USD

Dividend Yield

0%

Description

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. The company is headquartered in San Diego, California and currently employs 89 full-time employees. The company went IPO on 2015-04-15. The firm is focused on the discovery, development and commercialization of therapeutics designed for the care of patients facing serious fungal or viral infections. The firm's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. Rezafungin acetate is in Phase III of chemical trials. Its Cloudbreak antiviral platform consist of pipelines to develop Antiviral Conjugates (AVCs) for the prevention and treatment of influenza and other viral infections, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV) and the SARS-CoV-2 strains causing COVID-19. The firm's subsidiary includes Cidara Therapeutics United Kingdom Limited and Cidara Therapeutics (Ireland) Limited.

Contact

CALIFORNIA
San Diego
6310 Nancy Ridge Dr Ste 101
+18587526170.0
http://www.cidara.com/

IPO

2015-04-15

Employees

89

Officers

President, CEO & Executive Director
Dr. Jeffrey L. Stein Ph.D.
CFO, Chief Business Officer & Principal Accounting Officer
Dr. Preetam Shah M.B.A., Ph.D.
Chief Medical Officer
Dr. Taylor Sandison
Founder and Chief Strategy Officer
Dr. Kevin M. Forrest Ph.D.
COO & Chief Legal Officer
Mr. Shane M. Ward
Senior Vice President of People & Culture
Ms. Allison Lewis CCP, SPHR
Show More
Chief Scientific Officer
Dr. Leslie Tari Ph.D.
Senior Vice President of Clinical Operations
Ms. Laura A. Navalta
Senior VP of Translational Research & Development
Dr. Nicole Davarpanah J.D., M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one CDTX stock?

The intrinsic value of one CDTX stock under the Base Case scenario is 0.75 USD.

Is CDTX stock undervalued or overvalued?

Compared to the current market price of 13 USD, Cidara Therapeutics Inc is Overvalued by 94%.